First Quadrant L P CA held its position in Qiagen NV (NASDAQ:QGEN) during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 6,500 shares of the company’s stock at the end of the second quarter. First Quadrant L P CA’s holdings in Qiagen NV were worth $142,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Franklin Resources Inc. increased its position in Qiagen NV by 0.3% in the first quarter. Franklin Resources Inc. now owns 26,064,755 shares of the company’s stock valued at $580,982,000 after buying an additional 82,592 shares during the last quarter. BlackRock Fund Advisors increased its position in Qiagen NV by 6.7% in the first quarter. BlackRock Fund Advisors now owns 5,062,893 shares of the company’s stock valued at $113,105,000 after buying an additional 318,905 shares during the last quarter. State Street Corp increased its position in Qiagen NV by 3.0% in the first quarter. State Street Corp now owns 2,094,136 shares of the company’s stock valued at $46,785,000 after buying an additional 61,463 shares during the last quarter. Douglas Lane & Associates LLC acquired a new position in Qiagen NV during the first quarter valued at $42,915,000. Finally, Goldman Sachs Group Inc. increased its position in Qiagen NV by 59.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,448,832 shares of the company’s stock valued at $32,366,000 after buying an additional 539,870 shares during the last quarter. Hedge funds and other institutional investors own 58.78% of the company’s stock.

Shares of Qiagen NV (NASDAQ:QGEN) traded up 1.41% during midday trading on Friday, hitting $26.60. 1,767,404 shares of the stock were exchanged. Qiagen NV has a 52-week low of $19.94 and a 52-week high of $28.53. The firm has a market cap of $6.22 billion, a PE ratio of 53.20 and a beta of 0.90. The firm’s 50-day moving average is $26.52 and its 200 day moving average is $23.21.

Qiagen NV (NASDAQ:QGEN) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.24 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.01. Qiagen NV had a net margin of 9.13% and a return on equity of 9.21%. The firm earned $334.40 million during the quarter, compared to analyst estimates of $326.73 million. During the same quarter in the prior year, the firm earned $0.26 EPS. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. On average, analysts forecast that Qiagen NV will post $1.09 earnings per share for the current year.

Several equities analysts have recently weighed in on QGEN shares. Commerzbank AG reiterated a “buy” rating on shares of Qiagen NV in a research note on Friday, September 9th. Zacks Investment Research upgraded shares of Qiagen NV from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research report on Wednesday. DZ Bank AG restated a “buy” rating on shares of Qiagen NV in a research report on Monday, September 12th. Morgan Stanley set a $30.00 price objective on shares of Qiagen NV and gave the company a “buy” rating in a research report on Sunday, September 11th. Finally, TheStreet upgraded shares of Qiagen NV from a “hold” rating to a “buy” rating in a research report on Friday, July 29th. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $25.36.

Qiagen NV Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.

5 Day Chart for NASDAQ:QGEN

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with Analyst Ratings Network's FREE daily email newsletter.